menu
    • menu

    Company profile for ILiAD Biotechnologies

    NEW Drugs in Dev: 3
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ILiAD Biotechnologies (ILiAD) is a clinical stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. Our lead candidate is BPZE1, a live attenuated pertussis vaccine that is currently being studied in two fully enrolled Phase 2 clinical trials. BPZE1 is the most advanced next generation pertussis vaccine and has successfully completed two Phase 1 clinical studies. ILiAD Bio...
    ILiAD Biotechnologies (ILiAD) is a clinical stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. Our lead candidate is BPZE1, a live attenuated pertussis vaccine that is currently being studied in two fully enrolled Phase 2 clinical trials. BPZE1 is the most advanced next generation pertussis vaccine and has successfully completed two Phase 1 clinical studies. ILiAD Biotechnologies, LLC is a registered Delaware company founded in 2012.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ILiAD BiotechnologiesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Greater New York Area, East Coast, Northeastern US
    Telephone
    Telephone
    954-336-0777
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://iliadbio.com/index.html
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Iliad Biotech Reveals BPZE1 Phase 2B Results In Lancet Microbe
    Iliad Biotech Reveals BPZE1 Phase 2B Results In Lancet Microbe

    02 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251201920333/en/ILiAD-Biotechnologies-Announces-Lancet-Microbe-Publication-of-BPZE1-Phase-2b-Clinical-Results-in-Human-Challenge-Model

    BUSINESSWIRE
    02 Dec 2025
    Share Share
    ILiAD and hVIVO Sign LOI for BPZE1 Phase 3 Pertussis Vaccine Trial
    ILiAD and hVIVO Sign LOI for BPZE1 Phase 3 Pertussis Vaccine Trial

    27 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250127208008/en

    BUSINESSWIRE
    27 Jan 2025
    Share Share
    ILiAD Biotechnologies To Participate In Investor Conferences
    ILiAD Biotechnologies To Participate In Investor Conferences

    01 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241001001881/en

    BUSINESSWIRE
    01 Oct 2024
    Share Share
    Fierce Biotech Names ILiAD Biotechnologies to its 2024 Fierce 15
    Fierce Biotech Names ILiAD Biotechnologies to its 2024 Fierce 15

    05 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240802092354/en

    BUSINESSWIRE
    05 Aug 2024
    Share Share
    ILiAD Selects Emmes Group To Conduct Phase III Pertussis Vaccine Studies
    ILiAD Selects Emmes Group To Conduct Phase III Pertussis Vaccine Studies

    24 Jun 2024

    // CONTRACT PHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2024-06-24/iliad-selects-emmes-group-to-conduct-phase-iii-studies-of-pertussis-vaccine-candidate/9769

    CONTRACT PHARMA
    24 Jun 2024
    Share Share
    ILiAD Bio: Positive Phase 2b School-Age Data For Pertussis Vaccine BPZE1
    ILiAD Bio: Positive Phase 2b School-Age Data For Pertussis Vaccine BPZE1

    28 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240528492826/en

    BUSINESSWIRE
    28 May 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search